Effects of dipeptidyl peptidase IV inhibition on left ventricular compliance in obese mice with type II diabetes

被引：0
|
作者：
Hervent, A. -S. [1 ]
Hamdani, N. [2 ]
Matheeussen, V. [1 ]
Demolder, M. [1 ]
De Meester, I. [1 ]
Linke, W. A. [3 ]
Paulus, W. J. [2 ]
De Keulenaer, G. W. [1 ]
机构：
[1] Univ Antwerp, B-2020 Antwerp, Belgium
[2] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands
[3] Ruhr Univ Bochum, Bochum, Germany
来源：
EUROPEAN HEART JOURNAL | 2013年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：451 / 451
页数：1
相关论文
共 50 条
  • [21] Effects of SYR-322, a novel inhibitor of dipeptidyl peptidase-IV, alone or in combination with pioglitazone in obese and non-obese type 2 diabetes model rats and mice
    Takeuchi, Koji
    Moritoh, Yusuke
    Asakawa, Tomoko
    Kataoka, Osamu
    Zhang, Zhiyuan
    Odaka, Hiroyuki
    DIABETES, 2006, 55 : A465 - A465
  • [22] Metformin inhibits dipeptidyl peptidase IV activity in type 2 diabetes
    J. R. Lindsay
    N. Duffy
    A. M. McKillop
    J. Ardill
    F. P. M. O’Harte
    P. R. Flatt
    P. M. Bell
    Irish Journal of Medical Science, 2002, 171 (Suppl 5) : 29 - 29
  • [23] Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
    Gallwitz, Baptist
    IDRUGS, 2008, 11 (12) : 906 - 917
  • [24] Dipeptidyl peptidase-IV inhibitors: fixing type 2 diabetes?
    McIntyre, Hugh F.
    Grant, Paul
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2007, 68 (11) : 599 - 602
  • [25] Sitagliptin: A dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
    Miller, Shannon A.
    St. Onge, Erin L.
    ANNALS OF PHARMACOTHERAPY, 2006, 40 (7-8) : 1336 - 1343
  • [26] Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes - Potential importance of selectivity over dipeptidyl peptidases 8 and 9
    Lankas, GR
    Leiting, B
    Roy, RS
    Eiermann, GJ
    Beconi, MG
    Biftu, T
    Chan, CC
    Edmondson, S
    Feeney, WP
    He, HB
    Ippolito, DE
    Kim, D
    Lyons, KA
    Ok, HO
    Patel, RA
    Petrov, AN
    Pryor, KA
    Qian, XX
    Reigle, L
    Woods, A
    Wu, JK
    Zaller, D
    Zhang, XP
    Zhu, L
    Weber, AE
    Thornberry, NA
    DIABETES, 2005, 54 (10) : 2988 - 2994
  • [27] Dipeptidyl Peptidase Iv Inhibition Improves Chamber Compliance and Reduces Lv Hypertrophy in a Rodent Model of Myocardial Infarction With Diabetes
    Connelly, Kim A. Esq
    Golam, Kabir
    Desjardins, Jean Francois
    Thai, Kerri
    Advani, Suzanne L.
    Zhang, Yanling
    Yuen, Darren
    Advani, Andrew
    Gilbert, Richard E.
    CIRCULATION, 2011, 124 (21)
  • [28] Effects of the linagliptin, dipeptidyl peptidase-4 inhibitor, on bone fragility induced by type 2 diabetes mellitus in obese mice
    Kanda, Junkichi
    Furukawa, Megumi
    Izumo, Nobuo
    Shimakura, Taketoshi
    Yamamoto, Noriaki
    Takahashi, Hideaki E.
    Wakabayashi, Hiroyuki
    DRUG DISCOVERIES AND THERAPEUTICS, 2020, 14 (05): : 218 - 225
  • [29] MEDI 194-Design and synthesis of dipeptidyl peptidase IV inhibitor for the treatment of type II diabetes
    Tang Peng Cho
    Yang Fang Long
    Lin Zhi Gang
    Wang Qian
    Wang Yang
    Li Ya Li
    Zhang Lei
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2008, 236
  • [30] Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition
    Nagakura, T
    Yasuda, N
    Yamazaki, K
    Ikuta, H
    Tanaka, I
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2003, 52 (01): : 81 - 86
12345